
HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use LEVOTHYROXINE SODIUM TABLETS safely and effectively. See full prescribing information for LEVOTHYROXINE SODIUM TABLETS.

LEVOTHYROXINE SODIUM tablets, for oral use Initial U.S. Approval: 2002

WARNING: NOT FOR TREATMENT OF OBESITY OR F	OR WEIGHT LOSS
See full prescribing information for complete boxed warning	
Thyroid hormones, including Levothyroxine Sodium Tablets	s should not be used for
the treatment of obesity or for weight loss.	
 Doses beyond the range of daily hormonal requirements r even life threatening manifestations of toxicity (6, 10). 	hay produce serious or
RECENT MAJOR CHANGES	
Indications and Usage (1)	11/2023
Dosage and Administration (2.2, 2.3)	11/2023
Warnings and Precautions (5.1, 5.4)	11/2023
-	
INDICATIONS AND USAGE	
Levothyroxine Sodium Tablets are L-thyroxine (T4) indicated in adult and neonates, for:	pediatric patients, including
• Hypothyroidism: As replacement therapy in primary (thyroidal), second (hypothalamic) congenital or acquired hypothyroidism. (1)	dary (pituitary), and tertiary
 Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression radioiodine therapy in the management of thyrotropin-dependent well- 	
Limitations of Use	
 Not indicated for suppression of benign thyroid nodules and nontoxic or patients 	-
 Not indicated for treatment of hypothyroidism during the recovery pha 	ase of subacute thyroiditis
DOSAGE AND ADMINISTRATION	
Administer once daily, preferably on an empty stomach, one-half to or	
 Administer at least 4 hours before or after drugs that are known to inter Evaluate the need for does a divergents when regularly a draining the second seco	
• Evaluate the need for dose adjustments when regularly administering that may affect absorption. (2.1)	within one hour of certain foods
 Starting dose depends on a variety of factors, including age, body weight 	ght, cardiovascular status, and
concomitant medications. Peak therapeutic effect may not be attained	d for 4-6 weeks. (2.2)
• See full prescribing information for dosing in specific patient population	
 Adequacy of therapy determined with periodic monitoring of TSH and/o (2.4) 	or 14 as well as clinical status.
DOSAGE FORMS AND STRENGTHS Tablets: 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, and 300 mcg (
CONTRAINDICATIONS	
 Uncorrected adrenal insufficiency (4) 	
 Serious risks related to overtreatment or undertreatment with Levoth 	
the dose of Levothyroxine Sodium Tablets carefully and monitor respo	nse to titration. (5.1)
Cardiac adverse reactions in the elderly and in patients with underlyin Loweth reaving Sedium Tablete at less than the full replacement does	
Levothyroxine Sodium Tablets at less than the full replacement dose to cardiac adverse reactions, including atrial fibrillation. (2.3, 5.2, 8.5)	Decause of the increased risk of
 Myxedema coma: Do not use oral thyroid hormone drug products to t 	reat myxedema coma. (5.3)
• Acute adrenal crisis in patients with concomitant adrenal insufficiency.	

- Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacemen
 glucocorticoids prior to initiation of Levothyroxine Sodium Tablets treatment. (5.4)
- Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control

after starting, changing, or discontinuing thyroid hormone therapy. (5.5)

• Decreased bone mineral density associated with thyroid hormone over-replacement: Over-replacement can increase bone resorption and decrease bone mineral density. Give the lowest effective dose. (5.6)

Adverse reactions associated with Levothyroxine Sodium Tablets therapy are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Alvogen, Inc. at 1-866-770-3024 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium Tablets. (7)

Pregnancy may require the use of higher doses of Levothyroxine Sodium Tablets. (2.3, 8.1) See 17 for PATIENT COUNSELING INFORMATION.

Revised: 8/2024

FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS 1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Important Administration Instructions
- 2.2 Important Considerations for Dosing
- 2.3 Recommended Dosage and Titration
- 2.4 Monitoring TSH and/or Thyroxine (T4) Levels

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Serious Risks Related to Overtreatment or Undertreatment with Levothyroxine Sodium Tablets

5.2 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying

Cardiovascular Disease

- 5.3 Myxedema Coma
- 5.4 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency
- 5.5 Worsening of Diabetic Control

5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

- 7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics
- 7.2 Antidiabetic Therapy
- 7.3 Oral Anticoagulants
- 7.4 Digitalis Glycosides
- 7.5 Antidepressant Therapy
- 7.6 Ketamine
- 7.7 Sympathomimetics
- 7.8 Tyrosine-Kinase Inhibitors
- 7.9 Drug-Food Interactions

7.10 Drug-Laboratory Test Interactions

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation

- 8.4 Pediatric Use
- 8.5 Geriatric Use
- **10 OVERDOSAGE**

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

Thyroid hormones, including Levothyroxine Sodium Tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.

In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.

Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects[see Adverse Reactions (6), Drug Interactions (7.7), and Overdosage (10)].

1 INDICATIONS AND USAGE

Hypothyroidism

Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression

Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

<u>Limitations of Use</u>

- Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine Sodium Tablets may induce hyperthyroidism [see Warnings and Precautions (5.1)].
- Levothyroxine Sodium Tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Instructions

Administer Levothyroxine Sodium Tablets as a single daily dose, on an empty stomach, one-half to one hour before breakfast.

Administer Levothyroxine Sodium Tablets at least 4 hours before or after drugs known to interfere with Levothyroxine Sodium Tablets absorption [see Drug Interactions (7.1)].

Evaluate the need for dosage adjustments when regularly administering within one hour of certain foods that may affect Levothyroxine Sodium Tablets absorption [see Dosage and Administration (2.2 and 2.3), Drug Interactions (7.9) and Clinical Pharmacology (12.3)].

Administer Levothyroxine Sodium Tablets to pediatric patients who cannot swallow intact tablets by crushing the tablet, suspending the freshly crushed tablet in a small amount (5 to 10 mL) of water and immediately administering the suspension by spoon or dropper. Ensure the patient ingests the full amount of the suspension. Do not store the suspension. Do not administer in foods that decrease absorption of Levothyroxine Sodium Tablets, such as soybean-based infant formula [see Drug Interactions (7.9)].

2.2 Important Considerations for Dosing

The dosage of Levothyroxine Sodium Tablets for hypothyroidism or pituitary TSH suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food and the specific nature of the condition being treated [see Dosage and Administration (2.3), Warnings and Precautions (5), and Drug Interactions (7)]. Dosing must be individualized to account for these factors and dosage adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters [see Dosage and Administration (2.4)].

For adult patients with primary hypothyroidism, titrate until the patient is clinically euthyroid and the serum TSH returns to normal [see Dosage and Administration (2.3)].

For secondary or tertiary hypothyroidism, serum TSH is not a reliable measure of Levothyroxine Sodium Tablets dosage adequacy and should not be used to monitor therapy. Use the serum free-T4 level to titrate Levothyroxine Sodium Tablets dosing until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range [see Dosage and Administration (2.3)].

The peak therapeutic effect of a given dose of Levothyroxine Sodium Tablets may not be attained for 4 to 6 weeks.

2.3 Recommended Dosage and Titration

Primary, Secondary, and Tertiary Hypothyroidism in Adults

The recommended starting daily dosage of Levothyroxine Sodium Tablets in adults with primary, secondary, or tertiary hypothyroidism is based on age and comorbid cardiac conditions, as described in Table 1. For patients at risk of atrial fibrillation or patients with underlying cardiac disease, start with a lower dosage and titrate the dosage more slowly to avoid exacerbation of cardiac symptoms. Dosage titration is based on serum TSH or free-T4 [see Dosage and Administration (2.2)].

Table 1. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Adults*

Patient Population	Starting Dosage	Dosage Titration Based on Serum TSH or Free-T4
Adults diagnosed with	Full replacement dose is 1.6	Titrate dosage by 12.5 to 25 mcg

hypothyroidism	require a lower starting dose.	needed until the patient is euthyroid.
Adults at risk for atrial fibrillation or with underlying cardiac disease	Lower starting dose (less than 1.6 mcg/kg/day)	Titrate dosage every 6 to 8 weeks, as needed until the patient is euthyroid.
Geriatric patients	Lower starting dose (less than 1.6 mcg/kg/day)	

*Dosages greater than 200 mcg/day are seldom required. An inadequate response to daily dosages greater than 300 mcg/day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors *[see Dosage and Administration (2.1) and Drug Interactions (7)]*.

Primary, Secondary, and Tertiary Hypothyroidism in Pediatric Patients

The recommended starting daily dosage of Levothyroxine Sodium Tablets in pediatric patients with primary, secondary, or tertiary hypothyroidism is based on body weight and changes with age as described in Table 2. Titrate the dosage (every 2 weeks) as needed based on serum TSH or free-T4 until the patient is euthyroid [see Dosage and Administration (2.2)].

Table 2. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in PediatricPatients

Age	Starting Daily Dosage Per Kg Body Weight [*]
0-3 months	10-15 mcg/kg/day
3-6 months	8-10 mcg/kg/day
6-12 months	6-8 mcg/kg/day
1-5 years	5-6 mcg/kg/day
6-12 years	4-5 mcg/kg/day
Greater than 12 years but growth and puberty incomplete	2-3 mcg/kg/day
Growth and puberty complete	1.6 mcg/kg/day
	·

*Adjust dosage based on clinical response and laboratory parameters [see Dosage and Administration (2.4) and Use in Specific Populations (8.4)].

Pediatric Patients from Birth to 3 Months of Age at Risk for Cardiac Failure

Start at a lower starting dosage and increase the dosage every 4 to 6 weeks as needed based on clinical and laboratory response.

Pediatric Patients at Risk for Hyperactivity

To minimize the risk of hyperactivity, start at one-fourth the recommended full replacement dosage, and increase on a weekly basis by one-fourth the full recommended replacement dosage until the full recommended replacement dosage is reached.

Hypothyroidism in Pregnant Patients

For pregnant patients with pre-existing hypothyroidism, measure serum TSH and free-

T4 as soon as pregnancy is confirmed and, at minimum, during each trimester of pregnancy. In pregnant patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. The recommended daily dosage of Levothyroxine Sodium Tablets in pregnant patients is described in Table 3.

Table 3. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism inPregnant Patients

Patient Population	Starting Dosage	Dose Adjustment and Titration
hypothyroidism with	Pre-pregnancy dosage may increase during pregnancy	Increase Levothyroxine Sodium Tablets dosage by 12.5 to 25 mcg per day. Monitor TSH every 4 weeks until a stable dose is reached and serum TSH is within normal trimester-specific range. Reduce Levothyroxine Sodium Tablets dosage to pre- pregnancy levels immediately after delivery. Monitor serum TSH 4 to 8 weeks postpartum.
New onset hypothyroidism (TSH ≥ 10 mIU per liter)	1.6 mcg/kg/day	Monitor serum TSH every 4 weeks and adjust —Levothyroxine Sodium Tablets dosage until serum TSH is within normal trimester-specific range.
New onset hypothyroidism (TSH < 10 mIU per liter)	1.0 mcg/kg/day	

TSH Suppression in Well-differentiated Thyroid Cancer in Adult and Pediatric Patients

The Levothyroxine Sodium Tablets dosage is based on the target level of TSH suppression for the stage and clinical status of thyroid cancer.

2.4 Monitoring TSH and/or Thyroxine (T4) Levels

Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation. Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of Levothyroxine Sodium Tablets may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors.

Adults

In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dosage. In patients on a stable and appropriate replacement dosage, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient's clinical status.

Pediatric Patients

In patients with congenital hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T4. Monitor TSH and total or free-T4 in pediatric patients as follows: 2 and 4 weeks after the initiation of treatment, 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dosage stabilization until growth is completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals.

The general aim of therapy is to normalize the serum TSH level, TSH may not normalize in some patients due to in utero hypothyroidism causing a resetting of pituitary-thyroid feedback. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of Levothyroxine Sodium Tablets therapy and/or of the serum TSH to decrease below 20 units per liter within 4 weeks may indicate the patient is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of Levothyroxine Sodium Tablets [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)].

Secondary and Tertiary Hypothyroidism

Monitor serum free-T4 levels and maintain in the upper half of the normal range in these patients.

3 DOSAGE FORMS AND STRENGTHS

Levothyroxine Sodium Tablets, in the shape of caplet, are available as follows (Table 4):

Tablet Strength	Tablet Color	Tablet Markings
25 mcg	Orange	"T 4" and "25"
50 mcg	White	"T 4" and "50"
75 mcg	Violet	"T 4" and "75"
88 mcg	Mint Green	"T 4" and "88"
100 mcg	Yellow	"T 4" and "100"
112 mcg	Rose	"T 4" and "112"
125 mcg	Brown	"T 4" and "125"
137 mcg	Deep Blue	"T 4" and "137"
150 mcg	Light Blue	"T 4" and "150"
175 mcg	Lilac	"T 4" and "175"
200 mcg	Pink	"T 4" and "200"
300 mcg	Green	"T 4" and "300"

Table 4. Levothyroxine Sodium Tablets Tablet Strengths and Identifying Features

4 CONTRAINDICATIONS

Levothyroxine Sodium Tablets are contraindicated in patients with uncorrected adrenal insufficiency [see Warnings and Precautions (5.4)].

5 WARNINGS AND PRECAUTIONS

5.1 Serious Risks Related to Overtreatment or Undertreatment with Levothyroxine Sodium Tablets

Levothyroxine Sodium Tablets have a narrow therapeutic index. Overtreatment or undertreatment with Levothyroxine Sodium Tablets may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, gastrointestinal function, and glucose and lipid metabolism in adult or pediatric patients.

In pediatric patients with congenital and acquired hypothyroidism, undertreatment may adversely affect cognitive development and linear growth, and overtreatment is associated with craniosynostosis and acceleration of bone age [see Use in Specific Populations (8.4)].

Titrate the dose of Levothyroxine Sodium Tablets carefully and monitor response to titration to avoid these effects *[see Dosage and Administration (2.4)]*. Consider the potential for food or drug interactions and adjust the administration or dosage of

Levothyroxine Sodium Tablets as needed [see Dosage and Administration (2.1), Drug Interactions (7.1, 7.9), and Clinical Pharmacology (12.3)].

5.2 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease

Overtreatment with levothyroxine may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. Initiate Levothyroxine Sodium Tablets therapy in this population at lower doses than those recommended in younger individuals or in patients without cardiac disease [see Dosage and Administration (2.3) and Use in Specific Populations (8.5)].

Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive Levothyroxine Sodium Tablets therapy. Monitor patients receiving concomitant Levothyroxine Sodium Tablets and sympathomimetic agents for signs and symptoms of coronary insufficiency.

If cardiac symptoms develop or worsen, reduce the Levothyroxine Sodium Tablets dose or withhold for one week and restart at a lower dose.

5.3 Myxedema Coma

Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism, and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Use of oral thyroid hormone drug products is not recommended to treat myxedema coma. Administer thyroid hormone products formulated for intravenous administration to treat myxedema coma.

5.4 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency

Thyroid hormone increases metabolic clearance of glucocorticoids. Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with Levothyroxine Sodium Tablets [see Contraindications (4)].

5.5 Worsening of Diabetic Control

Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing Levothyroxine Sodium Tablets [see Drug Interactions (7.2)].

5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement

Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase, and suppressed serum parathyroid hormone levels. Administer the minimum dose of Levothyroxine Sodium Tablets that achieves the desired clinical and biochemical response to mitigate this risk.

6 ADVERSE REACTIONS

Adverse reactions associated with Levothyroxine Sodium Tablets therapy are primarily those of hyperthyroidism due to therapeutic overdosage *[see Warnings and Precautions*]

(5) and Overdosage (10)]. They include the following:

- *General:* fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating
- *Central nervous system:* headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia
- *Musculoskeletal:* tremors, muscle weakness, muscle spasm
- *Cardiovascular:* palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest
- Respiratory: dyspnea
- *Gastrointestinal:* diarrhea, vomiting, abdominal cramps, elevations in liver function tests
- *Dermatologic:* hair loss, flushing, rash
- Endocrine: decreased bone mineral density
- *Reproductive:* menstrual irregularities, impaired fertility

Seizures have been reported rarely with the institution of levothyroxine therapy.

Adverse Reactions in Pediatric Patients

Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants who have not undergone complete closure of the fontanelles, and in premature closure of the epiphyses in pediatric patients still experiencing growth with resultant compromised adult height.

Hypersensitivity Reactions

Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness, and wheezing. Hypersensitivity to levothyroxine itself is not known to occur.

7 DRUG INTERACTIONS

7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics

Many drugs can exert effects on thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium Tablets (Tables 5 to 8).

Table 5. Drugs That May Decrease T4 Absorption(Hypothyroidism)

Potential impact: Concurrent use may reduce the efficacy of Levothyroxine Sodium Tablets by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.

Drug or Drug Class	Effect
Phosphate Binders (e.g., calcium carbonate, ferrous sulfate, sevelamer, lanthanum)	Phosphate binders may bind to levothyroxine. Administer Levothyroxine Sodium Tablets at least 4 hours apart from these agents.
Orlistat	Monitor patients treated concomitantly with orlistat and Levothyroxine Sodium Tablets for

	changes in thyroid function.
Bile Acid	
Sequestrants	Bile acid sequestrants and ion exchange resins
(e.g., colesevelam,	are known to decrease levothyroxine absorption.
cholestyramine,	Administer Levothyroxine Sodium Tablets at least
colestipol)	4 hours prior to these drugs or monitor TSH
Ion Exchange Resins	levels.
(e.g., Kayexalate)	
Proton Pump	
Inhibitors	Gastric acidity is an essential requirement for
Sucralfate	adequate absorption of levothyroxine.
Antacids	Sucralfate, antacids and proton pump inhibitors
(e.g., aluminum &	may cause hypochlorhydria, affect intragastric
magnesium	pH, and reduce levothyroxine absorption.
hydroxides,	Monitor patients appropriately.
simethicone)	

Table 6. Drugs That May Alter T4 and Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism)

Drug or Drug Class	Effect	
Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin / Methadone 5-Fluorouracil Mitotane Tamoxifen	These drugs may increase serum thyroxine- binding globulin (TBG) concentration.	
Androgens / Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic Acid Potential impact (belo	These drugs may decrease serum TBG concentration. w): Administration of these agents with	
Levothyroxine Sodiur	m Tablets results in an initial transient increase in nistration results in a decrease in serum T4 and	
Salicylates (greater than 2 g/day)	Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%.	
Other drugs: Carbamazepine Furosemide (greater than 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-	These drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increase free T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total	

inflammatory Drugs	and free T4 may be reduced by 20% to 40%, but
- Fenamates	most patients have normal serum TSH levels and
	are clinically euthyroid. Closely monitor thyroid
	hormone parameters.

Table 7. Drugs That May Alter Hepatic Metabolism of T4(Hypothyroidism)

Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased Levothyroxine Sodium Tablets requirements.

Drug or Drug Class	Effect
	Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5'- diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine.

Table 8. Drugs That May Decrease Conversion of T4 to T3

Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased.

Drug or Drug Class	Effect
Beta-adrenergic antagonists (e.g., Propranolol greater than 160 mg/day)	In patients treated with large doses of propranolol (greater than 160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when a hypothyroid patient is converted to the euthyroid state.
Glucocorticoids (e.g., Dexamethasone <u>greater than or</u> <u>equal to</u> 4 mg/day)	Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (See above).
Other drugs: Amiodarone	Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients.

7.2 Antidiabetic Therapy

Addition of Levothyroxine Sodium Tablets therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control, especially when thyroid therapy is started, changed, or discontinued [see Warnings and Precautions (5.5)].

7.3 Oral Anticoagulants

Levothyroxine Sodium Tablets increase the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the Levothyroxine Sodium Tablets dose is increased. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments.

7.4 Digitalis Glycosides

Levothyroxine Sodium Tablets may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may decrease when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.

7.5 Antidepressant Therapy

Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and Levothyroxine Sodium Tablets may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. Levothyroxine Sodium Tablets may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on Levothyroxine Sodium Tablets may result in increased Levothyroxine Sodium Tablets requirements.

7.6 Ketamine

Concurrent use of ketamine and Levothyroxine Sodium Tablets may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients.

7.7 Sympathomimetics

Concurrent use of sympathomimetics and Levothyroxine Sodium Tablets may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.

7.8 Tyrosine-Kinase Inhibitors

Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Closely monitor TSH levels in such patients.

7.9 Drug-Food Interactions

Consumption of certain foods may affect Levothyroxine Sodium Tablets absorption thereby necessitating adjustments in dosing [see Dosage and Administration (2.1)]. Soybean flour, cottonseed meal, walnuts, and dietary fiber may bind and decrease the absorption of Levothyroxine Sodium Tablets from the gastrointestinal tract. Grapefruit juice may delay the absorption of levothyroxine and reduce its bioavailability.

7.10 Drug-Laboratory Test Interactions

Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free-T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentration. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens, and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

<u>Risk Summary</u>

The clinical experience, including data from postmarketing studies, in pregnant women treated with oral levothyroxine to maintain euthyroid state have not reported increased rates of major birth defects, miscarriages, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. Since TSH levels may increase during pregnancy, TSH should be monitored and Levothyroxine Sodium Tablets dosage adjusted during pregnancy (*see Clinical Considerations*). Animal reproductive studies have not been conducted with levothyroxine sodium. Levothyroxine Sodium Tablets should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-Associated Maternal and/or Embryo/Fetal Risk

Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre-eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development.

Dose Adjustments During Pregnancy and the Postpartum Period

Pregnancy may increase Levothyroxine Sodium Tablets requirements. Serum TSH levels should be monitored and the Levothyroxine Sodium Tablets dosage adjusted during pregnancy. Since postpartum TSH levels are similar to preconception values, the Levothyroxine Sodium Tablets dosage should return to the pre-pregnancy dose immediately after delivery [see Dosage and Administration (2.3)].

8.2 Lactation

Risk Summary

Published studies report that levothyroxine is present in human milk following administration of oral levothyroxine. No adverse effects on the breastfed infant have been reported and there is no information on the effects of levothyroxine on milk production. Adequate levothyroxine treatment during lactation may normalize milk production in hypothyroid lactating mothers with low milk supply. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Levothyroxine Sodium Tablets and any potential adverse effects on the breastfed infant from Levothyroxine Sodium Tablets or from the underlying maternal condition.

8.4 Pediatric Use

Levothyroxine Sodium Tablets are indicated in patients from birth to less than 17 years

of age:

- As a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
- As an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent well-differentiated thyroid cancer.

Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on cognitive development as well as on overall physical growth and maturation. Therefore, initiate Levothyroxine Sodium Tablets therapy immediately upon diagnosis. Levothyroxine is generally continued for life in these patients [see Warnings and Precautions (5.1)].

Closely monitor infants during the first 2 weeks of Levothyroxine Sodium Tablets therapy for cardiac overload and arrhythmias.

8.5 Geriatric Use

Because of the increased prevalence of cardiovascular disease among the elderly, initiate Levothyroxine Sodium Tablets at less than the full replacement dose [see Dosage and Administration (2.3) and Warnings and Precautions (5.2)]. Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly.

10 OVERDOSAGE

The signs and symptoms of overdosage are those of hyperthyroidism [see Warnings and Precautions (5) and Adverse Reactions (6)]. In addition, confusion and disorientation may occur.


Cerebral embolism, shock, coma, and death have been reported. Seizures occurred in a 3-year-old child ingesting 3.6 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium.

Reduce the Levothyroxine Sodium Tablets dose or discontinue temporarily if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient's medical status.

For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.

11 DESCRIPTION

Levothyroxine Sodium Tablets are L-thyroxine (T4) and contain the active ingredient, levothyroxine, a synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt. Synthetic T4 is chemically identical to that produced in the human thyroid gland. Levothyroxine (T4) sodium has an empirical formula of $C_{15}H_{10}I_4NNaO_4 \cdot H_2O$, molecular weight of 798.86 g/mol (anhydrous), and structural formula as shown:



Levothyroxine Sodium Tablets are for oral administration and are available in the following strengths: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg. Each levothyroxine sodium tablet contains the inactive ingredients butylated hydroxytoluene, calcium phosphate dibasic dihydrate, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate, and color additive(s). Table 9 provides a listing of the color additives by tablet strength:

Strength (mcg)	Color additive(s)
25	FD&C Yellow No. 6 Aluminum Lake [*]
50	None
75	FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake
88	FD&C Blue No. 1 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake*, D&C Yellow No. 10 Aluminum Lake
100	D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake*
112	D&C Red No. 27 & 30 Aluminum Lake
125	FD&C Yellow No. 6 Aluminum Lake*, FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake
137	FD&C Blue No. 1 Aluminum Lake
150	FD&C Blue No. 2 Aluminum Lake
175	FD&C Blue No. 1 Aluminum Lake, D&C Red No. 27 & 30 Aluminum Lake
200	FD&C Red No. 40 Aluminum Lake
300	D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake*, FD&C Blue No. 1 Aluminum Lake

Table 9. Levothyroxine Sodium Tablets Color Additives

* Note – FD&C Yellow No. 6 is orange in color.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.

The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral

tissues.

12.2 Pharmacodynamics

Oral levothyroxine sodium is a synthetic T4 hormone that exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present.

12.3 Pharmacokinetics

<u>Absorption</u>

Absorption of orally administered T4 from the gastrointestinal tract ranges from 40% to 80%. The majority of the Levothyroxine Sodium Tablets dose is absorbed from the jejunum and upper ileum. The relative bioavailability of Levothyroxine Sodium Tablets, compared to an equal nominal dose of oral levothyroxine sodium solution, is approximately 94%. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans. Dietary fiber decreases bioavailability of T4. Absorption may also decrease with age. In addition, many drugs and foods affect T4 absorption [see Drug Interactions (7)].

<u>Distribution</u>

Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T4 compared to T3. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins *[see Drug Interactions (7)]*. Thyroid hormones do not readily cross the placental barrier *[see Use in Specific Populations (8.1)]*.

<u>Elimination</u>

Metabolism

T4 is slowly eliminated (Table 10). The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately 80% of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amounts of T3 and reverse T3 (rT3). T3 and rT3 are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.

Excretion

Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age.

Table 10. Pharmacokinetic Parameters of Thyroid Hormones in EuthyroidPatients

Hormone	Ratio in Thyroglobulin	Biologic Potency	t _{1/2} (days)	Protein Binding (%)*
Levothyroxine (T4)	10 - 20	1	6-7**	99.96
Liothyronine (T3)	1	4	≤ 2	99.5

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term carcinogenicity studies in animals to evaluate the carcinogenic potential of levothyroxine have not been performed. Studies to evaluate mutagenic potential and animal fertility have not been performed.

16 HOW SUPPLIED/STORAGE AND HANDLING

Levothyroxine Sodium Tablets, in the shape of caplet are supplied as follows:

75 mcg - Violet - Imprint "T|4" and "75" NDC: 71335-1423-1 30 TABLET in a BOTTLE NDC: 71335-1423-2 100 TABLET in a BOTTLE NDC: 71335-1423-3 60 TABLET in a BOTTLE NDC: 71335-1423-4 90 TABLET in a BOTTLE NDC: 71335-1423-5 28 TABLET in a BOTTLE NDC: 71335-1423-6 10 TABLET in a BOTTLE 200 mcg - Pink - Imprint "T|4" and "200" NDC: 71335-1435-1 100 TABLET in a BOTTLE NDC: 71335-1435-2 30 TABLET in a BOTTLE NDC: 71335-1435-3 90 TABLET in a BOTTLE NDC: 71335-1435-4 60 TABLET in a BOTTLE NDC: 71335-1435-5 18 TABLET in a BOTTLE 88 mcg - Mint Green - Imprint "T|4" and "88" NDC: 71335-1438-1 30 TABLET in a BOTTLE NDC: 71335-1438-2 90 TABLET in a BOTTLE NDC: 71335-1438-3 28 TABLET in a BOTTLE NDC: 71335-1438-4 100 TABLET in a BOTTLE NDC: 71335-1438-5 60 TABLET in a BOTTLE 25 mcg - Orange - "T|4" and "25" NDC: 71335-1447-1 30 TABLET in a BOTTLE NDC: 71335-1447-2 90 TABLET in a BOTTLE NDC: 71335-1447-3 100 TABLET in a BOTTLE NDC: 71335-1447-4 60 TABLET in a BOTTLE NDC: 71335-1447-5 28 TABLET in a BOTTLE NDC: 71335-1447-6 10 TABLET in a BOTTLE 125 mcg - Brown - "T|4" and "125"

NDC: 71335-1456-1 30 TABLET in a BOTTLE NDC: 71335-1456-2 100 TABLET in a BOTTLE NDC: 71335-1456-3 90 TABLET in a BOTTLE NDC: 71335-1456-4 60 TABLET in a BOTTLE NDC: 71335-1456-5 28 TABLET in a BOTTLE 112 mcg - Rose - Imprint "T|4" and "112" NDC: 71335-1465-1 30 TABLET in a BOTTLE NDC: 71335-1465-2 90 TABLET in a BOTTLE NDC: 71335-1465-3 60 TABLET in a BOTTLE NDC: 71335-1465-4 18 TABLET in a BOTTLE NDC: 71335-1465-5 100 TABLET in a BOTTLE 100 mcg - Yellow - "T|4" and "100" NDC: 71335-1478-1 100 TABLET in a BOTTLE NDC: 71335-1478-2 30 TABLET in a BOTTLE NDC: 71335-1478-3 60 TABLET in a BOTTLE NDC: 71335-1478-4 7 TABLET in a BOTTLE NDC: 71335-1478-5 14 TABLET in a BOTTLE NDC: 71335-1478-6 90 TABLET in a BOTTLE NDC: 71335-1478-7 28 TABLET in a BOTTLE NDC: 71335-1478-8 56 TABLET in a BOTTLE NDC: 71335-1478-9 180 TABLET in a BOTTLE 50 mcg - White - Imprint "T|4" and "50" NDC: 71335-1502-1 30 TABLET in a BOTTLE NDC: 71335-1502-2 90 TABLET in a BOTTLE NDC: 71335-1502-3 100 TABLET in a BOTTLE NDC: 71335-1502-4 7 TABLET in a BOTTLE NDC: 71335-1502-5 14 TABLET in a BOTTLE NDC: 71335-1502-6 60 TABLET in a BOTTLE NDC: 71335-1502-7 21 TABLET in a BOTTLE NDC: 71335-1502-8 42 TABLET in a BOTTLE 150 mcg - Light Blue - Imprint "T|4" and "150" NDC: 71335-1512-1 30 TABLET in a BOTTLE NDC: 71335-1512-2 100 TABLET in a BOTTLE NDC: 71335-1512-3 90 TABLET in a BOTTLE NDC: 71335-1512-4 60 TABLET in a BOTTLE 137 mcg - Deep Blue - Imprint "T|4" and "137" NDC: 71335-1528-1 30 TABLET in a BOTTLE

NDC: 71335-1528-2 100 TABLET in a BOTTLE NDC: 71335-1528-3 90 TABLET in a BOTTLE NDC: 71335-1528-4 28 TABLET in a BOTTLE NDC: 71335-1528-5 60 TABLET in a BOTTLE 175 mcg - Lilac - Imprint "T|4" and "175" NDC: 71335-1637-1 30 TABLET in a BOTTLE NDC: 71335-1637-2 90 TABLET in a BOTTLE NDC: 71335-1637-3 100 TABLET in a BOTTLE NDC: 71335-1637-4 38 TABLET in a BOTTLE NDC: 71335-1637-5 28 TABLET in a BOTTLE NDC: 71335-1637-6 60 TABLET in a BOTTLE Storage and Handling

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C and 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect Levothyroxine Sodium Tablets from light and moisture.

Repackaged/Relabeled by:

Bryant Ranch Prepack, Inc.

Burbank, CA 91504

17 PATIENT COUNSELING INFORMATION

Inform the patient of the following information to aid in the safe and effective use of Levothyroxine Sodium Tablets:

Dosing and Administration

- Instruct patients to take Levothyroxine Sodium Tablets only as directed by their healthcare provider.
- Instruct patients to take Levothyroxine Sodium Tablets as a single dose, preferably on an empty stomach, one-half to one hour before breakfast.
- Inform patients that agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine. Instruct patients not to take Levothyroxine Sodium Tablets within 4 hours of these agents.
- Instruct patients to notify their healthcare provider if they are pregnant or breastfeeding or are thinking of becoming pregnant while taking Levothyroxine Sodium Tablets.

Important Information

- Inform patients that it may take several weeks before they notice an improvement in symptoms.
- Inform patients that the levothyroxine in Levothyroxine Sodium Tablets is intended to replace a hormone that is normally produced by the thyroid gland. Generally, replacement therapy is to be taken for life.
- Inform patients that Levothyroxine Sodium Tablets should not be used as a primary or adjunctive therapy in a weight control program.
- Instruct patients to notify their healthcare provider if they are taking any other medications, including prescription and over-the-counter preparations.
- Instruct patients to notify their physician of any other medical conditions they may have, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary

gland problems, as the dose of medications used to control these other conditions may need to be adjusted while they are taking Levothyroxine Sodium Tablets. If they have diabetes, instruct patients to monitor their blood and/or urinary glucose levels as directed by their physician and immediately report any changes to their physician. If patients are taking anticoagulants, their clotting status should be checked frequently.

• Instruct patients to notify their physician or dentist that they are taking Levothyroxine Sodium Tablets prior to any surgery.

Adverse Reactions

- Instruct patients to notify their healthcare provider if they experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event.
- Inform patients that partial hair loss may occur rarely during the first few months of Levothyroxine Sodium Tablets therapy, but this is usually temporary.

Manufactured by: LLOYD, Inc. Shenandoah, IA 51601 USA

Distributed by: Alvogen, Inc. Pine Brook, NJ 07058 USA

PI640-01

Levothyroxine Sodium 75mcg Tablet



Levothyroxine Sodium 200mcg Tablet



Each tablet contains: 200 mcg (0.2 mg) Levothyroxine Sodium, USP.

Keep this and all drugs out of the reach of children.

V 00371335143510 208820 11/13/2025 0123456789 Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from light and moisture.

Dispense in a tight, light-resistant container with a child-resistant closure.

Levothyroxine Sodium Tablets, USP

NDC 71335-1435-1





Levothyroxine Sodium 88 mcg Tablet




Each tablet contains: 88 mcg (0.088 mg) Levothyroxine Sodium, USP.

Keep this and all drugs out of the reach of children. V 00371335143817 208820 11/13/2025 0123456789

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP. Protect from light and moisture

Do not accept if seal over bottle opening is broken or missing.



NDC 71335-1438-1

88 mcg (0.088 mg)

BRP Repackaged by: Bryant Ranch Prepack, Inc.

Burbank, CA 91504 USA


Rx only

30 Tablets

LLOYD, Inc

Manufactured by:

Levothyroxine Sodium 25mcg Tablet



Levothyroxine Sodium 125mcg Tablet



Each tablet contains: Levothyroxine Sodium, USP 125 mcg (0.125 mg).

Keep this and all drugs out of the reach of children. V 00371335145613 208820 11/13/2025 0123456789

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from light and moisture.


Dispense in a tight, light-resistant container with a child-resistant closure.

Levothyroxine Sodium Tablets, USP 125 mcg (0.125 mg)

NDC 71335-1456-1




Levothyroxine Sodium 112mcg Tablet



PHARMACEUTICALS

Repackaged by: Bryant Ranch Prepack, Inc. Burbank, CA 91504 USA

Levothyroxine Sodium 100mcg Tablet



Levothyroxine Sodium 50 mcg Tablet



Each tablet contains: Levothyroxine Sodium, USP 50 mcg (0.05 mg).

Keep this and all drugs out of the reach of children. V 00371335150211 208820 11/13/2025 0123456789

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from light and moisture.

Dispense in a tight, light-resistant container with a child-resistant closure.

Levothyroxine Sodium Tablets, USP 50 mcg (0.05 mg)

NDC 71335-1502-1

PHARMACEUTICALS Repackaged by: Bryant Ranch Prepack, Inc. Burbank, CA 91504 USA




Rx only

30 Tablets


LLOYD Inc.

Manufactured by:

Levothyroxine Sodium 150mcg Tablet



Levothyroxine Sodium 137mcg Tablet



Levothyroxine Sodium 175mcg Tablet



Each tablet contains: Levothyroxine Sodium, USP 175 mcg (0.175 mg)

NDC 71335-1637-1


$\underbrace{\begin{array}{c} gm \sqsubseteq G \\ gm \sqsubseteq G \\ gm \vdash G \\ gm$

N 00371335163716 208820 11/13/2025 0123456789 Store at 20° to 25° C (68° to 77° F); excursions permitted to 15° to 30° C (59° to 86° F) (see USP controlled Room Temperature).

Take on empty stomach.

Dispense in a tight, light-resistant container as defined in USP.





	_	_
110		
00		
100	3	
-	` <u> </u>	
	_	_

LEVOTHYRC levothyroxine soc		DIUM							
Product Infor	mation								
Product Type	HUMAN PRESCRIPTION DRUGItem Code (Source)NDC:71335-1423(NDC:47781- 646)						DC:47781-		
Route of Admini	stration	ORAL							
Active Ingredi	Active Ingredient/Active Moiety								
	Ingredi	ent Name			Basis	of Strei	ngth	Strength	
		9J765S329G) (LEVOTHYR	OXINE -		OTHYRO	XINE SODI	-	75 ug	
UNII:Q51BO43MG4)				ANH	YDROUS			, 5 dg	
Inactive Ingre	dients								
		Ingredient Nam	е				S	trength	
MICROCRYSTALLII	NE CELLULOSE	(UNII: OP1R32D61U)							
DIBASIC CALCIUM	PHOSPHATE I	DIHYDRATE (UNII: 07TSZ	Z97GEP)						
POVIDONE, UNSPE	ECIFIED (UNII: F	Z989GH94E)							
SODIUM STARCH	GLYCOLATE TY	(PE A POTATO (UNII: 58	56J3G2A2	2)					
MAGNESIUM STEA	RATE (UNII: 700	097M6I30)							
BUTYLATED HYDR	OXYTOLUENE	(UNII: 1P9D0Z171K)							
FD&C RED NO. 40	(UNII: WZ B912	7XOA)							
FD&C BLUE NO. 2	(UNII: L06K8R7	DQK)							
Product Chara	octoristics								
Color		violot)	Score				2 piece	_	
	purple (capsule		Size				2 pieces 10mm	>	
Shape Flavor	capsule		Imprint	t Code			75;T;4		
Contains			mprint	Coue			, ,,,,,		
Packaging									
# Item Code	Pac	kage Description		Mark	eting S Date	Start		ting End ate	
1 NDC:71335- 1423-1	30 in 1 BOTTL Product	E; Type 0: Not a Combina	ation	12/13/20	19				
2 NDC:71335- 1423-2	100 in 1 BOTT Product	LE; Type 0: Not a Combir	nation	04/09/20	24				
, NDC:71335-	60 in 1 BOTTL	E; Type 0: Not a Combina	ation	04/00/20	71				

N	AC	NDA021116	05/07/2019			
	Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date		
P	larketing	Information				
6	NDC:71335- 1423-6	10 in 1 BOTTLE; Type 0: Not a Combination Product	04/09/2024			
5	NDC:71335- 1423-5	28 in 1 BOTTLE; Type 0: Not a Combination Product	04/09/2024			
4	NDC:71335- 1423-4	7 71 17/03/7019				
3	1423-3	Product	04/09/2024			

LEVOTHYROX levothyroxine sodiu		DIUM						
Product Inform	ation							
Product Type		HUMAN PRESCRI DRUG	PTION	ltem C (Sourc		NDC:713 668)	335-1435(N	DC:47781-
Route of Administ	tration	ORAL						
Active Ingredie	nt/Active	Moiety						
		ent Name			Basis	of Stre	nath	Strength
LEVOTHYROXINE SO UNII:Q51BO43MG4)	-		OTHYROXII	NE -	LEVOTHYRO ANHYDROUS	XINE SOD		200 ug
Inactive Ingred	ients							
		Ingredien	t Name				S	trength
MICROCRYSTALLINE								
DIBASIC CALCIUM P			: 07TSZ97	GEP)				
POVIDONE, UNSPEC								
SODIUM STARCH GL			UNII: 5856J:	3G2A2)				
MAGNESIUM STEARA BUTYLATED HYDRO			11/2)					
FD&C RED NO. 40 (L			IN)					
Product Charac	teristics							
Color	pink		Score				2 pieces	
Shape	caps	ule	Size				10mm	
Flavor			Imprint C	Code			200;T;4	
Contains								
Packaging								
# Item Code	Pac	kage Descrip	otion	I	Marketing S Date	Start		ing End ate
	00 in 1 BOTT roduct	LE; Type 0: Not a	Combinatio	on 12	/12/2019			
² 1435-2 P	roduct	E; Type 0: Not a (12	/12/2019			

	NDC:/1335- 1435-3	Product	E; Type U: NOT a Complination	¹ 12	/12/2019			
	NDC:71335- 1435-4	60 in 1 BOTTL Product	E; Type 0: Not a Combination	^ו 12	2/12/2019			
	NDC:71335- 1435-5	18 in 1 BOTTL Product	E; Type 0: Not a Combination	י 12	2/12/2019			
Μ	arketing	Informat	ion					
	Marketing Category	Applica	tion Number or Monogr Citation	aph	Marketing Date			ting End ate
ND		NDA021116			05/07/2019			
	VOTHYRC othyroxine soc		DIUM					
ev								
Pr	roduct Infor	mation						
Pr	oduct Type		HUMAN PRESCRIPTION DRUG	ltem C (Sourc		NDC:7133 649)	35-1438(N	DC:47781-
Ro	oute of Admini	stration	ORAL					
Ac	tive Ingredi	ent/Active	Moietv					
	g		ent Name		Basis	of Strer	nath	Strengt
	VOTHYROXINE S II:Q51BO43MG4)		9J765S329G) (LEVOTHYROXIN	IE -	LEVOTHYRO		-	88 ug
In	active Ingre	dients						
	.		Ingredient Name				S	trength
МІ	CROCRYSTALLI	NE CELLULOSI	(UNII: OP1R32D61U)					_
DIE	BASIC CALCIUM	PHOSPHATE	DIHYDRATE (UNII: 07TSZ97	GEP)				
	VIDONE, UNSPE							
	DIUM STARCH O		/DE A DOTATO /LINUL 505613					
			. ,	G2A2)				
MA	GNESIUM STEA	RATE (UNII: 70	097M6I30)	G2A2)				
MA BU	AGNESIUM STEA	RATE (UNII: 70 OXYTOLUENE	097M6I30) (UNII: 1P9D0Z171K)	3G2A2)				
MA BU FD	AGNESIUM STEA ITYLATED HYDR &C YELLOW NO	RATE (UNII: 70 OXYTOLUENE D. 6 (UNII: H77V	097M6I30) (UNII: 1P9D0Z171K) EI93A8)	3G2A2)				
MA BU FD D&	AGNESIUM STEA TYLATED HYDR &C YELLOW NO &C YELLOW NO.	 RATE (UNII: 70) OXYTOLUENE O. 6 (UNII: H77V 10 (UNII: 355V 	097M6I30) (UNII: 1P9D0Z171K) EI93A8) J5USQ3G)	3G2A2)				
MA BU FD D&	AGNESIUM STEA ITYLATED HYDR &C YELLOW NO	 RATE (UNII: 70) OXYTOLUENE O. 6 (UNII: H77V 10 (UNII: 355V 	097M6I30) (UNII: 1P9D0Z171K) EI93A8) J5USQ3G)	(G2A2)				
MA BU FD D& FD	AGNESIUM STEA TYLATED HYDR &C YELLOW NO &C YELLOW NO.	RATE (UNII: 70 OXYTOLUENE). 6 (UNII: H77V 10 (UNII: 35SV (UNII: H3R47K3	097M6I30) (UNII: 1P9D0Z171K) EI93A8) J5USQ3G)	(G2A2)				
MA BU FD D& FD	AGNESIUM STEA DTYLATED HYDR &C YELLOW NO &C YELLOW NO. &C BLUE NO. 1	RATE (UNII: 70 OXYTOLUENE). 6 (UNII: H77V 10 (UNII: 35SV (UNII: H3R47K3	097M6I30) (UNII: 1P9D0Z171K) EI93A8) /5USQ3G) /TBD)	SG2A2)	e		2 piec	:es
MA BU FD D& FD Pr Co	AGNESIUM STEA DTYLATED HYDR AC YELLOW NO AC YELLOW NO. AC BLUE NO. 1 TODUCT Chara	RATE (UNII: 70 OXYTOLUENE O. 6 (UNII: H77V 10 (UNII: 35SV (UNII: H3R47K3	097M6I30) (UNII: 1P9D0Z171K) EI93A8) /5USQ3G) /TBD)		e		2 piec 10mm	
MA BU FD D& FD Pr Co	AGNESIUM STEA DTYLATED HYDR AC YELLOW NO AC YELLOW NO. AC BLUE NO. 1 CODUCT Chara	RATE (UNII: 70 OXYTOLUENE D. 6 (UNII: H77V 10 (UNII: 35SV (UNII: H3R47K3 Acteristics green (mi	097M6I30) (UNII: 1P9D0Z171K) EI93A8) ØUSQ3G) TBD)	Score	e int Code			ı
MA BU FD D& FD Pr Co Sh	AGNESIUM STEA DTYLATED HYDR AC YELLOW NO AC YELLOW NO. AC BLUE NO. 1 T ODUCT Chara Nor	RATE (UNII: 70 OXYTOLUENE D. 6 (UNII: H77V 10 (UNII: 35SV (UNII: H3R47K3 Acteristics green (mi	097M6I30) (UNII: 1P9D0Z171K) EI93A8) ØUSQ3G) TBD)	Score			10mm	ı
MA BU FD D& FD Pr Co Sh Fla	AGNESIUM STEA DTYLATED HYDR AC YELLOW NO. AC YELLOW NO. AC BLUE NO. 1 TODUCT Chara Nor	RATE (UNII: 70 OXYTOLUENE D. 6 (UNII: H77V 10 (UNII: 35SV (UNII: H3R47K3 Acteristics green (mi	097M6I30) (UNII: 1P9D0Z171K) EI93A8) ØUSQ3G) TBD)	Score			10mm	ı
MA BU FD D& FD Co Sh Fla Co	AGNESIUM STEA DTYLATED HYDR AC YELLOW NO. AC YELLOW NO. AC BLUE NO. 1 TODUCT Chara Nor	RATE (UNII: 70 OXYTOLUENE D. 6 (UNII: H77V 10 (UNII: 35SV (UNII: H3R47K3 Acteristics green (mi	097M6I30) (UNII: 1P9D0Z171K) EI93A8) ØUSQ3G) TBD)	Score			10mm	ı
MA BU FD D& FD Co Sh Fla Co	AGNESIUM STEA DTYLATED HYDR AC YELLOW NO. AC YELLOW NO. AC BLUE NO. 1 TODUCT Chara Nor Dor Dape Avor Intains	RATE (UNII: 70) OXYTOLUENE D. 6 (UNII: H77V 10 (UNII: 35SV (UNII: H3R47K3 Acteristics green (mi capsule	097M6I30) (UNII: 1P9D0Z171K) EI93A8) ØUSQ3G) TBD)	Score Size Impri		itart	10mm 88;T;4 Market	ı
MA BU FD D& FD Co Sh Fla Co Pa #	AGNESIUM STEA DTYLATED HYDR AC YELLOW NO. AC YELLOW NO. AC BLUE NO. 1 TODUCT Chara Nor Dor Dape Avor Intains	RATE (UNII: 70 OXYTOLUENE D. 6 (UNII: H77V 10 (UNII: 35SV (UNII: H3R47K3 Acteristics green (mi capsule Pad	097M6I30) (UNII: 1P9D0Z171K) EI93A8) /5USQ3G) /TBD) nt green)	Score Size Impri	int Code Marketing S	itart	10mm 88;T;4 Market	ting End

3	NDC:71335- 1438-3	28 in 1 BOTTLE; Type 0: Not a Combination Product	12/16/2019		
4	NDC:71335- 1438-4	100 in 1 BOTTLE; Type 0: Not a Combination Product	12/16/2019		
S NDC:71335- 1438-5 60 in 1 BOTTLE; Type 0: Not a Combination Product 12/16/2019					
Ν	larketing	nformation			
	Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
NE	A	NDA021116	05/07/2019		

LEVOTHYROXINE levothyroxine sodium tabl							
	el						
Product Information							
Product Type	human pr Drug	RESCRIPTION	ltem Coo (Source		NDC:71335- 640)	1447(NI	DC:47781-
Route of Administration	ORAL						
Active Ingredient/Act	ive Moiety						
Ingi	redient Nam	e		Basis	of Strengt	th	Strength
LEVOTHYROXINE SODIUM (UUNII:Q51BO43MG4)	JNII: 9J765S3290	G) (LEVOTHYROXI	NE -	LEVOTHYRO ANHYDROUS	XINE SODIUM		25 ug
Inactive Ingredients							
	Ingre	dient Name				S	trength
MICROCRYSTALLINE CELLU	LOSE (UNII: OPI	LR32D61U)					
DIBASIC CALCIUM PHOSPHA	TE DIHYDRAT	E (UNII: 07TSZ97	'GEP)				
POVIDONE, UNSPECIFIED (U	INII: FZ989GH94	IE)					
SODIUM STARCH GLYCOLAT	Е ТҮРЕ А РОТ	ATO (UNII: 5856J	3G2A2)				
MAGNESIUM STEARATE (UNI	I: 70097M6I30)						
BUTYLATED HYDROXYTOLU	ENE (UNII: 1P9D	DOZ171K)					
FD&C YELLOW NO. 6 (UNII: I	H77VEI93A8)						
Product Characterist	ics						
Color	orange	Score			2 pi	eces	
Shape	capsule	Size			10n	nm	
Flavor		Imprint	Code		25;	Т;4	

Ρ	Packaging									
#	ltem Code	Package Description	Marketing Start Date	Marketing End Date						
1	NDC:71335- 1447-1	30 in 1 BOTTLE; Type 0: Not a Combination Product	12/24/2019							
2	NDC:71335- 1447-2	90 in 1 BOTTLE; Type 0: Not a Combination Product	12/24/2019							
3	NDC:71335- 1447-3	100 in 1 BOTTLE; Type 0: Not a Combination Product	12/24/2019							

Contains

	Category	Citation	Date	Date			
MarketingApplication Number or MonographMarketing StartMarketing EndCategoryCitationDateDate							
Μ	larketing l	nformation					
6	NDC:71335- 1447-6						
5	NDC:71335- 1447-5						
4	NDC:71335- 1447-4						

LEVOTHYRO	XINE SO	DIUM						
levothyroxine sod	ium tablet							
Product Inform	nation							
Product Type		HUMAN PRESCRI DRUG	PTION	ltem Co (Source		NDC:71 657)	335-1456(NI	DC:47781-
Route of Adminis	stration	ORAL						
Active Ingredie	ent/Active	Moiety						
	Ingredi	ent Name			Basis	of Stre	ength	Strength
LEVOTHYROXINE S UNII:Q51BO43MG4)	ODIUM (UNII:	9J765S329G) (LEV	OTHYROXIN	IE -	LEVOTHYRO ANHYDROUS		NUM	125 ug
Inactive Ingree	dients							
		Ingredien	t Name				S	trength
MICROCRYSTALLIN	IE CELLULOSI	(UNII: OP1R32D6	51U)					
DIBASIC CALCIUM	PHOSPHATE	DIHYDRATE (UNII	: 07TSZ97	GEP)				
POVIDONE, UNSPE	CIFIED (UNII: I	Z989GH94E)						
SODIUM STARCH G	LYCOLATE TY		UNII: 5856J3	G2A2)				
MAGNESIUM STEA		-						
BUTYLATED HYDRO			1K)					
FD&C YELLOW NO								
FD&C RED NO. 40								
FD&C BLUE NO. 1	(UNII: H3R47K3	TBD)						
Due duet Cheve								
Product Chara			6				2	
Color	brov		Score				2 pieces	
Shape 	caps	sule	Size				10mm	
Flavor			Imprint C	ode			125;T;4	
Contains								
Packaging								
# Item Code	Pa	ckage Descrip	otion	М	larketing S Date	Start		ing End ite
1 NDC:71335- 1456-1	30 in 1 BOTTL Product	E; Type 0: Not a (Combinatior	01/0)7/2020		De	

01/07/2020

100 in 1 BOTTLE; Type 0: Not a Combination Product

2 NDC:71335-1456-2

	Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date			
	_						
N	Marketing Information						
5	NDC:71335- 1456-5	28 in 1 BOTTLE; Type 0: Not a Combination Product	01/07/2020				
4	NDC:71335- 1456-4	60 in 1 BOTTLE; Type 0: Not a Combination Product	01/07/2020				
3	NDC:71335- 1456-3	90 in 1 BOTTLE; Type 0: Not a Combination Product	01/07/2020				

LEVOTHYROXINE	SO	DIUM						
levothyroxine sodium tab								
Product Information	ו							
Product Type		HUMAN PRESCRIPTIO	ON	ltem Co (Source		NDC:713 654)	35-1465(N	NDC:47781-
Route of Administration	n	ORAL						
Active Ingredient/Ac	tive	Moiety						
Ing	gredie	ent Name			Basis	of Stre	ngth	Strength
LEVOTHYROXINE SODIUM UNII:Q51BO43MG4)	(UNII: 9	9J765S329G) (LEVOT	HYROXI	NE -	LEVOTHYRO ANHYDROUS		UM	112 ug
Inactive Ingredients								
		Ingredient N	lame				9	Strength
MICROCRYSTALLINE CELLU		•	,					
DIBASIC CALCIUM PHOSPH			7TSZ97	'GEP)				
POVIDONE, UNSPECIFIED (•			20242				
SODIUM STARCH GLYCOLA			I: 5856J	3G2A2)				
MAGNESIUM STEARATE (UN BUTYLATED HYDROXYTOL								
D&C RED NO. 27 (UNII: 2LRS		. ,						
D&C RED NO. 30 (UNII: 254								
Product Characteris	tics							
Color	red (re	ose)	Score	•			2 pieces	
Shape	CAPSU	JLE	Size				10mm	
Flavor			Impri	nt Code			112;T;4	
Contains								

P	Packaging						
#	Item Code	Package Description	Marketing Start Date	Marketing End Date			
1	NDC:71335- 1465-1	30 in 1 BOTTLE; Type 0: Not a Combination Product	05/07/2019				
2	NDC:71335- 1465-2	90 in 1 BOTTLE; Type 0: Not a Combination Product	05/07/2019				

3	1465-3	Product	05/07/2019	
4	NDC:71335- 1465-4	18 in 1 BOTTLE; Type 0: Not a Combination Product	05/07/2019	
5	NDC:71335- 1465-5	100 in 1 BOTTLE; Type 0: Not a Combination Product	05/07/2019	
Μ	larketing	Information		
M	larketing Marketing Category	Information Application Number or Monograph Citation	Marketing Start Date	Marketing End Date

LEVOTHYRO levothyroxine sod		DIUM						
Product Inform	nation							
Product Type		HUMAN PRESCRI DRUG	PTION	ltem Co (Source		NDC:71 651)	.335-1478(N	NDC:47781-
Route of Adminis	stration	ORAL						
Active Ingredie	ent/Active	Moiety						
	Ingred	ient Name			Basis	of Stre	ength	Strength
LEVOTHYROXINE S UNII:Q51BO43MG4)	ODIUM (UNII:	9J765S329G) (LEV	OTHYROXII	NE -	LEVOTHYRO ANHYDROUS		DIUM	100 ug
Inactive Ingree	alents							
		Ingredien					9	Strength
MICROCRYSTALLIN								
DIBASIC CALCIUM			: 0715297	GEP)				
POVIDONE, UNSPE								
SODIUM STARCH G			UNII: 5856J:	3GZAZ)				
MAGNESIUM STEAL	•		עו)					
FD&C YELLOW NO		•	IN)					
D&C YELLOW NO.	•							
Product Chara	cteristics							
Color	yell	ow	Score				2 pieces	
Shape	cap	sule	Size				10mm	
Flavor			Imprint C	Code			100;T;4	
Contains								
Packaging								
# Item Code	Pa	ckage Descrip	otion	Ν	larketing S Date	Start		ting End ate

 #
 Item Code
 Package Description
 Item Code
 Date

 1
 NDC:71335-1478-1
 100 in 1 BOTTLE; Type 0: Not a Combination Product
 01/16/2020

 2
 NDC:71335-1478-2
 30 in 1 BOTTLE; Type 0: Not a Combination Product
 01/16/2020

3	NDC:/1335- 1478-3	ou in I BUTTLE; Type U: Not a Combination Product	01/16/2020				
4	NDC:71335- 1478-4	7 in 1 BOTTLE; Type 0: Not a Combination Product	01/16/2020				
5	NDC:71335- 1478-5	14 in 1 BOTTLE; Type 0: Not a Combination Product	01/16/2020				
6	NDC:71335- 1478-6	90 in 1 BOTTLE; Type 0: Not a Combination Product	01/16/2020				
7	NDC:71335- 1478-7	28 in 1 BOTTLE; Type 0: Not a Combination Product	01/16/2020				
8	NDC:71335- 1478-8	56 in 1 BOTTLE; Type 0: Not a Combination Product	01/16/2020				
9	NDC:71335- 1478-9	180 in 1 BOTTLE; Type 0: Not a Combination Product	01/16/2020				
R	Marketing Information						
1	arketing						
	Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date			

NDA

NDA021116

05/07/2019

LEVOTHYROXINE S							
Product Information							
Product Type	HUMAN PRESCRI DRUG	IPTION	ltem Co (Source		NDC:7133 643)	35-1502(N	DC:47781-
Route of Administration	ORAL						
Active Ingredient/Acti	ve Moiety						
Ingr	edient Name			Basis	of Strer	ngth	Strengt
LEVOTHYROXINE SODIUM (U UNII:Q51BO43MG4)	NII: 9J765S329G) (LE)	VOTHYROXII	NE -	LEVOTHYRO ANHYDROUS		UM	50 ug
Inactive Ingredients							
	Ingredien	t Name				S	trength
MICROCRYSTALLINE CELLUL	OSE (UNII: OP1R32D	61U)					
DIBASIC CALCIUM PHOSPHA	TE DIHYDRATE (UNI	I: 07TSZ97	GEP)				
POVIDONE, UNSPECIFIED (UI							
SODIUM STARCH GLYCOLAT		(UNII: 5856J	3G2A2)				
MAGNESIUM STEARATE (UNII		0					
BUTYLATED HYDROXYTOLUE	NE (UNII: 1P9D0Z17	1K)					
Product Characteristi	cs						
Color	white	Score			2	2 pieces	
Shape	capsule	Size			1	10mm	
Flavor		Imprint (Code		5	50;T;4	
Contains							
Packaging							
# Itom Code	Packago Doccriu	ntion	М	arketing S	Start	Market	ing End

#	item Code	Раскаде резсприон	Date	Date
1	NDC:71335- 1502-1	30 in 1 BOTTLE; Type 0: Not a Combination Product	02/24/2020	
2	NDC:71335- 1502-2			
3	NDC:71335- 1502-3	100 in 1 BOTTLE; Type 0: Not a Combination Product	02/24/2020	
4	NDC:71335- 1502-4			
5	NDC:71335- 1502-5			
6	NDC:71335- 1502-6			
7	NDC:71335- 1502-7	21 in 1 BOTTLE; Type 0: Not a Combination Product	02/24/2020	
8	NDC:71335- 1502-8	42 in 1 BOTTLE; Type 0: Not a Combination Product	02/24/2020	
M	larkoting	Information		
I	larketing	intormation		
	Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NC	A	NDA021116	05/07/2019	
LE	EVOTHYRO	DXINE SODIUM		

levothyroxine sodium tablet **Product Information** Item Code HUMAN PRESCRIPTION NDC:71335-1512(NDC:47781-**Product Type** DRUG (Source) 662) **Route of Administration** ORAL **Active Ingredient/Active Moiety** Ingredient Name Strength **Basis of Strength** LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE -LEVOTHYROXINE SODIUM 150 ug UNII:Q51BO43MG4) ANHYDROUS **Inactive Ingredients**

	Ingredien	it Name	Strength				
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)							
DIBASIC CALCIUM PHO	DIBASIC CALCIUM PHOSPHATE DIHYDRATE (UNII: O7TSZ97GEP)						
POVIDONE, UNSPECIFI	ED (UNII: FZ989GH94E)						
SODIUM STARCH GLYC	OLATE TYPE A POTATO	(UNII: 5856J3G2A2)					
MAGNESIUM STEARATI	E (UNII: 70097M6I30)						
BUTYLATED HYDROXY	TOLUENE (UNII: 1P9D0Z17	1K)					
FD&C BLUE NO. 2 (UNI	I: L06K8R7DQK)						
Product Characte	eristics						
Color	blue (light blue)	Score	2 pieces				
Shape	capsule	Size	10mm				
Flavor		Imprint Code	150;T;4				
Contains							

Pa	ackaging						
#	ltem Code	Pac	kage Description	I	Marketing S Date	Start	Marketing End Date
1	NDC:71335- 1512-1	30 in 1 BOTTL Product	E; Type 0: Not a Combination	02	/18/2020		
2	NDC:71335- 1512-2	100 in 1 BOTT Product	LE; Type 0: Not a Combination	02	/18/2020		
3	NDC:71335- 1512-3	90 in 1 BOTTL Product	E; Type 0: Not a Combination	02	/18/2020		
4	NDC:71335- 1512-4	60 in 1 BOTTL Product	E; Type 0: Not a Combination	02	/18/2020		
Μ	larketing	Informat	ion				
M	larketing Marketing Category		ion tion Number or Monogra Citation	ph	Marketing Date		Marketing End Date
	Marketing Category		tion Number or Monogra				
	Marketing Category	Applicat	tion Number or Monogra		Date		
NC	Marketing Category	Applicat	tion Number or Monogra Citation		Date		
	Marketing Category	Applicat NDA021116	tion Number or Monogra Citation		Date		
	Marketing Category	Applicat NDA021116	tion Number or Monogra Citation		Date		
NC LE	Marketing Category	Applicat NDA021116 DXINE SO dium tablet	tion Number or Monogra Citation		Date		
NC LE lev	Marketing Category A S EVOTHYRC rothyroxine soc	Applicat NDA021116 DXINE SO dium tablet	tion Number or Monogra Citation		Date 05/07/2019 ode		

Active Ingredient/Active Moiety					
Ingredient Name	Basis of Strength	Strength			
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51B043MG4)	LEVOTHYROXINE SODIUM ANHYDROUS	137 ug			

Inactive Ingredients	
Ingredient Name	Strength
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
DIBASIC CALCIUM PHOSPHATE DIHYDRATE (UNII: O7TSZ97GEP)	
POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)	
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)	
FD&C BLUE NO. 1 (UNII: H3R47K3TBD)	
Product Characteristics	

Color	blue (deep blue)	Score	2 pieces
Shape	capsule	Size	10mm
Flavor		Imprint Code	137;T;4
Contains			

Packaging

#	ltem Code	Pa	ckage Description		M	arketing : Date	start		eting End Date
1	NDC:71335- 1528-1	30 in 1 BOTTLE; Type 0: Not a Combination Product			03/0	5/2020			
2	NDC:71335- 1528-2	100 in 1 BOTTLE; Type 0: Not a Combination Product			03/0	5/2020			
3	NDC:71335- 1528-3	90 in 1 BOTTLE; Type 0: Not a Combination Product			03/0	5/2020			
4	NDC:71335- 1528-4	28 in 1 BOTTLE; Type 0: Not a Combination Product			03/05/2020				
5	NDC:71335- 1528-5	60 in 1 BOTTLE; Type 0: Not a Combination Product			03/0	5/2020			
Μ	larketing	Informat	ion						
	Marketing Category	Applica	tion Number or Monog Citation			Marketing Date	-		
NC	A	NDA021116			05	5/07/2019			
E	VOTHYRO	OXINE SO	DIUM						
<u>،</u>	othyroxine so	dium tablet							
Ρ	roduct Infor	mation							
Product Type			HUMAN PRESCRIPTION DRUG	ltem (Sou	n Code NDC:71335-16 urce) 665)		35-1637(NDC:47781-	
R	oute of Admini	stration	ORAL						
۵	ctive Ingredi	ent/Active	Mojety						
`		-	ent Name			Racio	of Stre	nath	Strengt
LE		-	9J765S329G) (LEVOTHYROXI	INE -		LEVOTHYRO	XINE SOD	•	175 ug
٦N	III:Q51BO43MG4)					ANHYDROUS			175 dg
In	active Ingre	dients							
			Ingredient Name						Strength
41	CROCRYSTALLI	NE CELLULOS	E (UNII: OP1R32D61U)						
D	BASIC CALCIUM	PHOSPHATE	DIHYDRATE (UNII: 07TSZ97	7GEP)					
o	VIDONE, UNSPI	ECIFIED (UNII:	FZ989GH94E)						
60	DIUM STARCH	GLYCOLATE T	YPE A POTATO (UNII: 5856)	3G2A2))				
1/	AGNESIUM STEA	RATE (UNII: 70	097M6I30)						
3 L	JTYLATED HYDR	OXYTOLUENE	(UNII: 1P9D0Z171K)						
= C	&C BLUE NO. 1	(UNII: H3R47K3	BTBD)						
56	C RED NO. 27	UNII: 2LRS185U	I6K)						
30	C RED NO. 30 (UNII: 2542T280	98B)						
PI	roduct Chara	acteristics							

Color	purple (lilac)	Score	2 pieces
Shape	capsule	Size	10mm
Flavor		Imprint Code	175;T;4
Contains			

Packaging

#	ltem Code	Package Description	Marketing Start Date	Marketing End Date	
1	NDC:71335- 1637-1	30 in 1 BOTTLE; Type 0: Not a Combination Product	06/09/2020		
2	NDC:71335- 1637-2	90 in 1 BOTTLE; Type 0: Not a Combination Product			
3	NDC:71335- 1637-3	100 in 1 BOTTLE; Type 0: Not a Combination Product			
4	NDC:71335- 1637-4	38 in 1 BOTTLE; Type 0: Not a Combination Product	06/09/2020		
5	NDC:71335- 1637-5	28 in 1 BOTTLE; Type 0: Not a Combination Product	06/09/2020		
6	NDC:71335- 1637-6	60 in 1 BOTTLE; Type 0: Not a Combination Product	06/09/2020		
Marketing Information					
Marketing Category		Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
	A	NDA021116	05/07/2019		

Labeler - Bryant Ranch Prepack (171714327)

Establishment

Name	Address	ID/FEI	Business Operations
Bryant Ranch Prepack		171714327	REPACK(71335-1423, 71335-1435, 71335-1438, 71335-1447, 71335-1456, 71335-1465, 71335-1478, 71335-1502, 71335-1512, 71335-1528, 71335-1637), RELABEL(71335-1423, 71335-1435, 71335-1438, 71335-1447, 71335-1456, 71335-1465, 71335-1478, 71335-1502, 71335-1512, 71335-1528, 71335-1637)

Revised: 8/2024

Bryant Ranch Prepack